Complementary and alternative medicine use among individuals participating in research: Implications for research and practice

Pharmacotherapy

Volumn 26, Issue 12 I, 2006, Pages 1794-1801

  Welder, Gregory J ^a   Wessel, Timothy R ^b   Arant, Christopher B ^b   Schofield, Richard S ^b,c   Zineh, Issam ^a,d  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

Alternative medicine; CAM; Clinical study; Complementary and alternative medicine; Complementary medicine; Confounding variable; Drug interaction; Practice; Research

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CALCIUM; CHONDROITIN; CHROMIUM; CYANOCOBALAMIN; FISH OIL; FOLIC ACID; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GREEN TEA EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IRON; LINOLEIC ACID; LINSEED OIL; MAGNESIUM; MELATONIN; METHOTREXATE; MINERAL; PHOSPHATIDYLCHOLINE; RETINOL; SELENIUM; UNINDEXED DRUG; VITAMIN; VITAMIN B COMPLEX; XANTHOPHYLL; ZEAXANTHIN; ZINC;

ADULT; ALTERNATIVE MEDICINE; ARTICLE; CLINICAL EXAMINATION; DATA BASE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL RESEARCH; PATIENT PARTICIPATION; PROSPECTIVE STUDY; UNIVERSITY; UNSPECIFIED SIDE EFFECT; VOLUNTEER;

ADULT; AGE FACTORS; CLINICAL TRIALS; COMPLEMENTARY THERAPIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DRUG INTERACTIONS; FEMALE; HERB-DRUG INTERACTIONS; HUMANS; MALE; MINERALS; PLANT PREPARATIONS; PROSPECTIVE STUDIES; RESEARCH SUBJECTS; SEX FACTORS; VITAMINS;

EID: 33845361395     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.12.1794     Document Type: Article

References (81)

1. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998;280:1569-75.
2. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data 2004:1-19.
3. Wootton JC, Sparber A. Surveys of complementary and alternative medicine: part I. General trends and demographic groups. J Altern Complement Med 2001;7:195-208.
4. Institute of Medicine. Complementary and alternative medicine (CAM) in the United States. Washington, DC: National Academies, 2005.
5. Taylor DM, Walsham N, Taylor SE, Wong L. Potential interactions between prescription drugs and complementary and alternative medicines among patients in the emergency department. Pharmacotherapy 2006;26:634-40.
6. Skidmore-Roth L. Mosby's handbook of herbs & natural supplements, 2nd ed. St. Louis, MO: Mosby 2004.
7. Kim SR, Nakanishi K, Itagaki Y, Sparrow JR. Photooxidation of A2-PE, a photoreceptor outer segment fluorophore, and protection by lutein and zeaxanthin. Exp Eye Res 2006;82:828-39.
8. You JS, Huang HF, Chang YL. Panax ginseng reduces adriamycin-induced heart failure in rats. Phytother Res 2005;19:1018-22.
9. Li YG, Zhang F, Wang ZT, Hu ZB. Identification and chemical profiling of monacolins in red yeast rice using high-performance liquid chromatography with photodiode array detector and mass spectrometry. J Pharm Biomed Anal 2004;35:1101-12.
10. Din JN, Newby DE, Flapan AD. Omega 3 fatty acids and cardiovascular disease: fishing for a natural treatment. BMJ 2004;328:30-5.
11. Kris-Etherton PM, Hecker KD, Binkoski AE. Polyunsaturated fatty acids and cardiovascular health. Nutr Rev 2004;62:414-26.
12. Duvoisin RC, Yahr MD, Cote LD. Pyridoxine reversal of L-dopa effects in Parkinsonism. Trans Am Neurol Assoc 1969;94:81-4.
13. MGI Pharma. Hexalen (altretamine) package insert. Bloomington, MN; 2001.
14. Wiernik PH, Yeap B, Vogl SE, et al. Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern cooperative oncology group. Cancer Invest 1992;10:1-9.
15. Hansson O, Sillanpaa M. Pyridoxine and serum concentration of phenytoin and phenobarbitone [letter]. Lancet 1976;1:256.
16. 6 augmentation of tricyclic antidepressant treatment in geriatric depression with cognitive dysfunction. J Am Coll Nutr 1992;11:159-63.
17. University of Maryland Medical Center, Maryland Medical Center Programs, Center for Integrative Medicine. Supplements by name. Available from http://www.ummm.edu/altmed/ConsLookups/Supplements.html. Accessed January 22, 2006.
18. Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. Clin Cancer Res 1998;4:1567-71.
19. Elasmar SA, Saad ED, Hoff PM. Case report: hand-foot syndrome induced by the oral fluoropyrimidine S-1. Jpn J Clin Oncol 2001;31:172-4.
20. Vidrio H. Interaction with pyridoxal as a possible mechanism of hydralazine hypotension. J Cardiovasc Pharmacol 1990;15:150-6.
21. Kos Pharmaceuticals. Niaspan (niacin extended-release tablets) package insert. Miami, FL; 2003.
22. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41:343-70.
23. Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med 1994;121:833-41.
24. 12, pantothenic acid, biotin and choline. Washington, DC: National Academies, 1998.
25. Novartis Pharmaceuticals. Desferal (deferoxamine mesylate for injection USP) package insert. East Hanover, NJ; 2002.
26. Abbott Laboratories. Cenolate (ascorbic acid, vitamin C injection) package insert. North Chicago, IL; 2002.
27. Mitchell BG, Clements JA, Pottage A, Prescott LF. Mexiletine disposition: individual variation in response to urine acidification and alkalinisation. Br J Clin Pharmacol 1983;16:281-4.
28. Gonzalez JP, Valdivieso A, Calvo R, et al. Influence of vitamin C on the absorption and first pass metabolism of propranolol. Eur J Clin Pharmacol 1995;48:295-7.
29. Houston JB, Levy G. Drug biotransformation interactions in man VI: acetaminophen and ascorbic acid. J Pharm Sci 1976;65:1218-21.
30. Lee MG, Chiou WL. Mechanism of ascorbic acid enhancement of the bioavailability and diuretic effect of furosemide. Drug Metab Dispos 1998;26:401-7.
31. Axcan Scandipharm. Photofrin (porfimer) package insert. Birmingham, AL; 2003.
32. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 2000;57:1221-7.
33. Novartis Ophthalmics. Visudyne (verteporfin for injection) package insert. Duluth, GA; 2003.
34. Scuntaro I, Kientsch U, Wiesmann UN, Honegger UE. Inhibition by vitamin E of drug accumulation and of phospholipidosis induced by desipramine and other cationic amphiphilic drugs in human cultured cells. Br J Pharmacol 1996;119:829-34.
35. Gogu SR, Beckman BS, Rangan SR, Agrawal KC. Increased therapeutic efficacy of zidovudine in combination with vitamin E. Biochem Biophys Res Commun 1989;165:401-7.
36. Glaxo SmithKline. Lanoxin (digoxin) package insert. Research Triangle Park, NC; 2001.
37. Ovation Pharmaceuticals. Peganone (ethotoin) package insert. Deerfield, IL; 2003.
38. Carter BL, Garnett WR, Pellock JM, Stratton MA, Howell JR. Effect of antacids on phenytoin bioavailability. Ther Drug Monit 1981;3:333-40.
39. Borcherding SM, Stevens R, Nicholas RA, Corley CR, Self T. Quinolones: a practical review of clinical uses, dosing considerations, and drug interactions. J Fam Pract 1996;42:69-78.
40. Martec Pharmaceuticals. Carafate (sucralfate) package insert. Kansas City, MO; 1997.
41. Neuvonen PJ. Interactions with the absorption of tetracyclines. Drugs 1976;11:45-54.
42. Singh N, Weisler SL, Hershman JM. The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. Thyroid 2001;11:967-71.
43. Merck and Co. Fosamax (alendronate) package insert. Whitehouse Station, NJ; 2004.
44. Proctor & Gamble Pharmaceuticals. Actonel (risedronate) package insert. Cincinnati, OH; 2003.
45. Novartis Pharmaceuticals. Miacalcin (calcitonin) package insert. East Hanover, NJ; 2003.
46. Abbott Laboratories. Calcium chloride 10% (calcium chloride) package insert. Chicago, IL; 2000.
47. McManus MC. Neuromuscular blockers in surgery and intensive care, part 2. Am J Health Syst Pharm 2001;58:2381-95.
48. Gora ML, Seth SK, Bay WH, Visconti JA. Milk-alkali syndrome associated with use of chlorothiazide and calcium carbonate. Clin Pharm 1989;8:227-9.
49. Buckley MS, Goff AD, Knapp WE. Fish oil interaction with warfarin. Ann Pharmacother 2004;38:50-2.
50. Schoene NW. Vitamin E and omega-3 fatty acids: effectors of platelet responsiveness. Nutrition 2001;17:793-6.
51. Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 1993;88:523-33.
52. Berkenboom G, Brekine D, Unger P, Richelle M, Carpentier Y, Fontaine J. Effect of dietary supplementation with fish oil on cyclosporine A-induced vascular toxicity. Cardiovasc Drugs Ther 1996;10:379-85.
53. Chan DC, Watts GF, Mori TA, Barrett PH, Beilin LJ, Redgrave TG. Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. Eur J Clin Invest 2002;32:429-36.
54. al-Harbi MM, Islam MW, al-Shabanah OA, al-Gharably NM. Effect of acute administration of fish oil (omega-3 marine triglyceride) on gastric ulceration and secretion induced by various ulcerogenic and necrotizing agents in rats. Food Chem Toxicol 1995;33:553-8.
55. Kroboth PD, Salek FS, Pittenger AL, Fabian TJ, Frye RF. DHEA and DHEA-S: a review. J Clin Pharmacol 1999;39:327-48.
56. Frye R, Kroboth P, Folan M, et al. Effect of DHEA on CYP3A4-mediated metabolism of triazolam [abstr]. Clin Pharmacol and Ther 2000;67:109.
57. Jesse RL, Loesser K, Eich DM, Qian YZ, Hess ML, Nestler JE. Dehydroepiandrosterone inhibits human platelet aggregation in vitro and in vivo. Ann N Y Acad Sci 1995;774:281-90.
58. Watson Pharmaceuticals. Androderm (testosterone transdermal system) package insert. Corona, CA; 1999.
59. Melchior CL, Ritzmann RF. Dehydroepiandrosterone enhances the hypnotic and hypothermic effects of ethanol and pentobarbital. Pharmacol Biochem Behav 1992;43:223-7.
60. Klann RC, Holbrook CT, Nyce JW. Chemotherapy of murine colorectal carcinoma with cisplatin and cisplatin plus 3′-deoxy-3′- azidothymidine. Anticancer Res 1992;12:781-7.
61. Yang JY, Schwartz A, Henderson EE. Inhibition of 3′-azido-3′- deoxythymidine-resistant HIV-1 infection by dehydroepiandrosterone in vitro. Biochem Biophys Res Commun 1994;201:1424-32.
62. Rozenfeld V, Crain JL, Callahan AK. Possible augmentation of warfarin effect by glucosamine-chondroitin. Am J Health Syst Pharm 2004;61:306-7.
63. Zhang JS, Imai T, Otagiri M. Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin. Arch Toxicol 2000;74:300-7.
64. Vaes LP, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother 2000;34:1478-82.
65. Hu Z, Yang X, Ho PC, et al. Herb-drug interactions: a literature review. Drugs 2005;65:1239-82.
66. Yoshioka M, Ohnishi N, Koishi T, et al. Studies on interactions between functional foods or dietary supplements and medicines. IV. Effects of ginkgo biloba leaf extract on the pharmacokinetics and pharmacodynamics of nifedipine in healthy volunteers. Biol Pharm Bull 2004;27:2006-9.
67. Anderson LA, Hakojarvi SL, Boudreaux SK. Zinc acetate treatment in Wilson's disease. Ann Pharmacother 1998;32:78-87.
68. Abbott Laboratories. Calcium disodium versenate (edetate calcium disodium injection, USP) package insert. Chicago, IL; 2000.
69. Troost FJ, Brummer RJ, Dainty JR, Hoogewerff JA, Bull VJ, Saris WH. Iron supplements inhibit zinc but not copper absorption in vivo in ileostomy subjects. Am J Clin Nutr 2003;78:1018-23.
70. Astin JA. Why patients use alternative medicine: results of a national study. JAMA 1998;279:1548-53.
71. Foster DF, Phillips RS, Hamel MB, Eisenberg DM. Alternative medicine use in older Americans. J Am Geriatr Soc 2000;48:1560-5.
72. Mackenzie ER, Taylor L, Bloom BS, Hufford DJ, Johnson JC. Ethnic minority use of complementary and alternative medicine (CAM): a national probability survey of CAM utilizers. Altern Ther Health Med 2003;9:50-6.
73. Ni H, Simile C, Hardy AM. Utilization of complementary and alternative medicine by United States adults: results from the 1999 national health interview survey. Med Care 2002;40:353-8.
74. Vogel JH, Bolling SF, Costello RB, et al, for the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine). Integrating complementary medicine into cardiovascular medicine. J Am Coll Cardiol 2005;46:184-221.
75. Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004;76:323-9.
76. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 1998;83:777-82.
77. Neuhouser ML, Patterson RE, Schwartz SM, Hedderson MM, Bowen DJ, Standish LJ. Use of alternative medicine by children with cancer in Washington state. Prev Med 2001;33:347-54.
78. Gerson-Cwilich R, Serrano-Olvera A, Villalobos-Prieto A. Complementary and alternative medicine (CAM) in Mexican patients with cancer. Clin Transi Oncol 2006;8:200-7.
79. Nahleh Z, Tabbara IA. Complementary and alternative medicine in breast cancer patients. Palliat Support Care 2003;1:267-73.
80. Wiygul JB, Evans BR, Peterson BL, et al. Supplement use among men with prostate cancer. Urology 2005;66:161-6.
81. Helyer LK, Chin S, Chui BK, et al. The use of complementary and alternative medicines among patients with locally advanced breast cancer - a descriptive study. Available from http://www.biomedcentral.com/1471-2407/6/39.